北京大学学报(医学版) ›› 2024, Vol. 56 ›› Issue (5): 942-945. doi: 10.19723/j.issn.1671-167X.2024.05.031

• 短篇论著 • 上一篇    

含铋剂四联疗法根除幽门螺杆菌的疗效:4 261例患者的真实世界研究

管仁珍1,2, 丁士刚1, 石岩岩3, 薛艳1,*()   

  1. 1 北京大学第三医院消化内科,北京 100191
    2 滕州市中心人民医院消化内科,山东滕州 2775002
    3 北京大学第三医院临床流行病学研究中心,北京 100191
  • 收稿日期:2022-11-26 出版日期:2024-10-18 发布日期:2024-10-16
  • 通讯作者: 薛艳 E-mail:xueyanby@163.com
  • 基金资助:
    北京大学第三医院临床队列建设项目和北京大学第三医院临床重点项目(BYSY2017026)

仁珍 管1,2, 士刚 丁1, 岩岩 石3, 艳 薛1,*()   

  • Received:2022-11-26 Online:2024-10-18 Published:2024-10-16
  • Contact: 艳 薛 E-mail:xueyanby@163.com
  • Supported by:
    the Clinical Cohort Construction Program of Peking University Third Hospital and the Key Clinical Projects of Peking University Third Hospital(BYSY2017026)

RICH HTML

  

关键词: 幽门螺杆菌, 枸橼酸铋钾, 米诺环素, 根除率

中图分类号: 

  • R573.1

表1

不同年龄、性别的患者Hp根除率的比较"

Category Eradication failure Eradication successful Total Eradication rate/% χ2 P value
Gender 0.002 0.961
  Male 83 1 981 2 064 96.0
  Female 89 2 108 2 197 95.9
Age/years 0.046 0.830
   < 60 141 3 378 3 519 96.0
  ≥60 31 711 742 95.8

表2

不同质子泵抑制剂组Hp根除率的比较"

Section Example number Eradication failure Eradication successful Eradication rate/%
Group A 383 14 369 96.3
Group B 1 461 60 1 401 95.7
Group C 1 841 78 1 763 95.7
Group D 576 20 556 96.5
χ2value 0.826
P value 0.843

表3

不同抗生素组合组Hp根除率的比较"

Antibiotic group Example number Eradication failure Eradication successful Eradication rate/%
Group a 1 067 21 1 046 98.0
Group b 2 544 131 2 413 94.8
Group c 188 9 179 95.2
Group d 179 2 177 98.9
Group e 230 11 219 95.2
Group f 53 0 53 100.0
Fisher value 28.436
P value < 0.001

表4

不同质子泵抑制剂间各种不同抗生素组合组Hp根除率的比较"

Group Antibiotic group Example number Eradication failure Eradication successful Eradication rate/% χ2value P value
Group A Group a 87 1 86 98.8 5.071 0.024
Group b 201 16 185 92.0
Group B Group a 374 9 365 97.6 4.448 0.035
Group b 874 44 830 95.0
Group C Group a 351 8 343 97.7 4.783 0.029
Group b 1 243 62 1 181 95.0
Group D Group a 255 3 252 98.8 3.878 0.049
Group b 226 9 217 96.0
1 吕秋菊, 蒲强红. CYP2C19基因多态性对含左氧氟沙星方案根除幽门螺杆菌疗效影响的Meta分析[J]. 中国医药导刊, 2017, 19 (11): 1174- 1180.
doi: 10.3969/j.issn.1009-0959.2017.11.026
2 刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 中华消化杂志, 2017, 37 (6): 364- 378.
doi: 10.3760/cma.j.issn.0254-1432.2017.06.002
3 Nagy P , Johansson S , Molloy-Bland M . Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA[J]. Gut Pathog, 2016, 8, 8.
doi: 10.1186/s13099-016-0091-7
4 Cai Q , Zhu C , Yuan Y , et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: A nationwide multicentre study[J]. Gut, 2019, 68 (9): 1576- 1587.
doi: 10.1136/gutjnl-2018-317556
5 Bakhti SZ , Latifi-Navid S , Zahri S . Unique constellations of five polymorphic sites of Helicobacter pylori vacA and cagA status associated with risk of gastric cancer[J]. Infect Genet Evol, 2020, 79, 104167.
doi: 10.1016/j.meegid.2019.104167
6 Bartpho TS , Wattanawongdon W , Tongtawee T , et al. Precan-cerous gastric lesions with Helicobacter pylori vacA+/babA2+/oipA+ genotype increase the risk of gastric cancer[J]. Biomed Res Int, 2020, 2020, 7243029.
7 Sugano K , Tack J , Kuipers EJ , et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64 (9): 1353- 1367.
doi: 10.1136/gutjnl-2015-309252
8 Graham DY , Lu H , Yamaoka Y . A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12 (4): 275- 278.
doi: 10.1111/j.1523-5378.2007.00518.x
9 张建中. 中国幽门螺杆菌治疗低根除率现状及应对策略[J]. 胃肠病学和肝病学杂志, 2017, 26 (6): 637- 639.
doi: 10.3969/j.issn.1006-5709.2017.06.005
10 李一凡, 胡庆林, 费繁荣, 等. 深圳市17 589例体检人群中幽门螺杆菌分型结果分析[J]. 国际检验医学杂志, 2021, 42 (16): 1921- 1924.
doi: 10.3969/j.issn.1673-4130.2021.16.001
11 Mamori S , Higashida A , Kawara F , et al. Age-dependent eradication of Helicobacter pylori in Japanese patients[J]. World J Gastroenterol, 2010, 16 (33): 4176- 4179.
doi: 10.3748/wjg.v16.i33.4176
12 Meyer JM , Silliman NP , Wang W , et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999[J]. Ann Intern Med, 2002, 136 (1): 13- 24.
doi: 10.7326/0003-4819-136-1-200201010-00008
13 Liang X , Xu X , Zheng Q , et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study[J]. Clin Gastroenterol Hepatol, 2013, 11 (7): 802- 807.
doi: 10.1016/j.cgh.2013.01.008
14 Chen Q , Zhang W , Fu Q , et al. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy[J]. Am J Gastroenterol, 2016, 111 (12): 1736- 1742.
doi: 10.1038/ajg.2016.443
15 Bai P , Zhou LY , Xiao XM , et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients[J]. J Dig Dis, 2015, 16 (8): 464- 470.
doi: 10.1111/1751-2980.12271
16 Zhang YX , Zhou LY , Song ZQ , et al. Primary antibiotic resis-tance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study[J]. World J Gastroenterol, 2015, 21 (9): 2786- 2792.
doi: 10.3748/wjg.v21.i9.2786
[1] 田雪丽,宋志强,索宝军,周丽雅,李彩玲,张雨欣. 比较Epsilometer试验法和琼脂稀释法检测幽门螺杆菌对甲硝唑的敏感性[J]. 北京大学学报(医学版), 2023, 55(5): 934-938.
[2] 侯卫华,宋书杰,石中月,金木兰. 幽门螺杆菌阴性早期胃癌的临床病理特征[J]. 北京大学学报(医学版), 2023, 55(2): 292-298.
[3] 王子靖,李在玲. 有幽门螺杆菌感染家族史儿童胃部菌群的特点[J]. 北京大学学报(医学版), 2021, 53(6): 1115-1121.
[4] 王立新, 许晓, 倪耀丰, 孙海涛, 余日月, 魏世成. 载药脂质体修饰的聚醚醚酮植入物的抑菌和骨整合性能[J]. 北京大学学报(医学版), 2021, 53(4): 758-763.
[5] 程小娥,彭慧浈,户雪雪,冯小金,马龙先,蒋昌宇,柳涛. 米诺环素抑制甲醛炎性痛及机制[J]. 北京大学学报(医学版), 2018, 50(5): 797-804.
[6] 朱林,王聿栋,董艳梅,陈晓峰. 缓释米诺环素的介孔纳米生物玻璃载药系统[J]. 北京大学学报(医学版), 2018, 50(2): 249-255.
[7] 石岩岩, 丁士刚, 张婷, 鲁凤民 , 张静, 王晔. 幽门螺杆菌硫氧还蛋白-1基因克隆及其重组蛋白表达与活性测定[J]. 北京大学学报(医学版), 2014, 46(2): 190-194.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!